Celregen Therapeutics In-Licenses iPS Therapy for Cornea Transplants in $100 Million Deal

Hangzhou Celregen Therapeutics signed a $100 million agreement to in-license China rights for a novel therapy that uses induced Pluripotent Stem Cells to repair bullous keratopathy, a blister-like swelling of the cornea. Celregen, a subsidiary of Shanghai Fosun Pharma, acquired the rights from Japan’s Cellusion, a regenerative medicine startup. Currently, bullous keratopathy is treated by transplanting a donated cornea, but the number of donated corneas covers only 1% of the global need. Fosun’s Celregen, which focuses on regenerative medicine and cell therapy, was incubated by Fosun Health Capital’s New Drug Fund. More details....

Share this with colleagues: